15 October 2020 - - US-based bioproduction tools and services provider BioLife Solutions, Inc's (NASDAQ: BLFS) recently acquired SciSafe division has been awarded a two year contract from a large pharmaceutical company for cold chain management and storage of COVID-19 vaccines, the company said.

The contract value is approximately USD 2.7m.

Management estimates that SciSafe will contribute approximately USD 9m in incremental revenue in 2021.

Founded in 2010, SciSafe offers dedicated pharmaceutical and biological specimen storage in its four fully cGMP-compliant sample management facilities.

SciSafe has built flourishing relationships with a marquee list of the world's leading and most admired organizations.

Clients have repeatedly chosen to store their most valued and irreplaceable biological samples because they trust SciSafe to care for them as if they were their own.

SciSafe values and respects its long-term client relationships.

With over 60 years combined experience specifically in life sciences, SciSafe personnel fully appreciate the vital requirements of all areas of specimen storage and cold chain management.

BioLife Solutions is a supplier of a portfolio of class-defining cell and gene therapy bioproduction tools and services.

Its tools portfolio includes our proprietary CryoStor freeze media and HypoThermosol shipping and storage media, ThawSTAR family of automated, water-free thawing products, evo cold chain management system, and Custom Biogenic Systems high capacity storage freezers.

Services include SciSafe biologic and pharmaceutical materials storage.